<?xml version="1.0" encoding="UTF-8"?>
<p>A number of vaccine approaches for MPV have been investigated. The F protein is conserved between subgroups, immunogenic, and the only target of neutralizing antibodies; in contrast to RSV, the MPV G protein does not induce neutralizing antibodies and is not a protective antigen [
 <xref ref-type="bibr" rid="CR206">206</xref>, 
 <xref ref-type="bibr" rid="CR209">209</xref>, 
 <xref ref-type="bibr" rid="CR214">214</xref>]. A recombinant parainfluenza virus encoding the MPV F protein demonstrated protection against MPV [
 <xref ref-type="bibr" rid="CR339">339</xref>], and soluble F protein vaccines reduced viral titers in cotton rats and hamsters [
 <xref ref-type="bibr" rid="CR207">207</xref>, 
 <xref ref-type="bibr" rid="CR208">208</xref>]. Reverse genetics technology has been developed for MPV and has been used to produce recombinant strains for vaccine development [
 <xref ref-type="bibr" rid="CR197">197</xref>, 
 <xref ref-type="bibr" rid="CR340">340</xref>]. Viruses lacking the G, M2-1, M2-2, or SH proteins or with point mutations are attenuated and immunogenic in rodent and primate models [
 <xref ref-type="bibr" rid="CR197">197</xref>, 
 <xref ref-type="bibr" rid="CR221">221</xref>, 
 <xref ref-type="bibr" rid="CR341">341</xref>â€“
 <xref ref-type="bibr" rid="CR344">344</xref>].
</p>
